Replimune Group, Inc. (REPL)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Replimune Group, Inc. (REPL) is listed on Nasdaq, where it has traded since July 20, 2018.
- Listed On
- Nasdaq
- Listed Since
- July 20, 2018
- Employees
- 465
- Market Cap
- $1.2B
About Replimune Group, Inc.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 192 institutions reported holding REPL, with 95.3 million shares worth $1.1 billion in aggregate. The largest reported holder was Baker Bros. Advisors, with 11.0 million shares worth $122.3 million. Of the 5 largest holders listed below, 1 opened a new position in REPL, 3 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Baker Bros. Advisors | 11,045,336 | $122M | Unchanged |
| BlackRock | 8,958,535 | $99M | Added 43.58% |
| Rtw Investments | 7,411,581 | $82M | Added 0.74% |
| Ridgeback Capital Investments | 7,310,656 | $81M | New position |
| Goldman Sachs | 4,541,018 | $50M | Added 99.41% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is REPL?
Replimune Group, Inc. (REPL) is listed on Nasdaq, where it has traded since July 20, 2018.
Who are the largest institutional holders of REPL?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of REPL were Baker Bros. Advisors, BlackRock and Rtw Investments.
How many institutions own REPL?
192 institutions reported a position in REPL for the quarter ended June 30, 2026, worth $1.1 billion in total.
Did institutions buy or sell REPL last quarter?
Of the 5 largest reported holders, 1 opened a new position in REPL, 3 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for REPL.
Every reported institutional holder, plus insider and congressional trades in REPL, on SentiSense.